• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bacterial nanostructures developed to locally deliver proteins

October 24, 2016 By Sarah Faulkner

Bacterial nanostructures developed to locally deliver proteinsSpanish researchers demonstrated that bacterial inclusion bodies, non-toxic nanostructures, hold promise for a sustained, local delivery of protein drugs by mimicking components of a mammal’s endocrine system.

New materials developed as controllable, localized systems of drug delivery often aim to be immobilized in a given tissue as a drug “depot” for long term supply of the drug. Hydrogels, polymers, and other biomaterials have been researched as scaffolds for drug delivery, but toxicity and rejection can present issues in the system’s long-term stability.

The team of researchers turned to the endocrine system, which uses secretory granules to accumulate functional proteins for long-term storage. In response to particular stimuli, the reservoirs will release their hormones. Bacterial inclusion bodies can mimic the function of secretory granules; they are mechanically stable and can retain active protein for localized delivery of a therapeutic protein. Previous work shows that the bacterial nanostructures can successfully penetrate mammalian cells.

Researchers evaluated the bacterial inclusion bodies as a potential delivery system for a protein that induces apoptosis, or cell death, upon local delivery to targeted tumor tissues, according to a study published today in Nature. 

They determined that local injection was the best delivery method of the nanostructures. Upon injection of the bacterial inclusion bodies, the team observed high stability and low toxicity. The nanostructures also successfully induced apoptosis in the targeted tissue.

The team concluded that bacterial inclusion bodies can mimic the secretory granules of the endocrine system and behave as depots of functional proteins upon their immobilization by local injection.

Filed Under: Featured, Nanoparticles, Oncology, Research & Development

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS